In a first study, we have adapted a systems vaccinology approach developed for human to pigs and demonstrated its capacity in identifying early immune signatures in the blood relating to adaptive immune responses against Mycoplasma hyopneumoniae. This approach represents an important step in a more rational design of efficacious vaccines for pigs. A subsequent study assessed the efficacy of innovative vaccine formulations against Mycoplasma hyopneumoniae which were able to induce cellular immunity.

The review paper outlines the major limitations of the commercial vaccines, reviews the different experimental M. hyopneumoniae vaccines that have been developed and tested in mice and pigs, and discusses possible avenues for further research to develop better vaccines and to achieve a more sustainable control of M. hyopneumoniae infections.